[Press release] Oncodesign and Servier reach a key first milestone in their strategic partnership on LRRK2 inhibitors for Parkinson’s Disease



[Congress] EMIM !NEW DATES! 25-28 August 2020 – Thessaloniki – Greece

[Congress] EMIM  NEW DATES 25-28 August 2020 – Thessaloniki –  Greece

LAST MINUTE INFORMATION: Given the rapidly evolving COVID-19 coronavirus outbreak, the 15th European Molecular Imaging Meeting have been POSTPONED at the 25-28 August.

Our teams remains available for any of your projects. Don't hesitate to contact us!

I fix a meeting

Meet Cyril Berthet, Pharmaco-imaging Unit Director, at EMIM!

It takes 2 to tango: compound labeling and complementary imaging approaches to show how your compound works & targets the right patient.  

Through pharmaco-imaging, the results of preclinical studies can influence the early decision to continue or interrupt the development of a drug candidate. In the clinical development phase, imaging offers an exceptional opportunity to follow the drug in humans with the same techniques developed during the preclinical phase. Novel therapies are converging towards precision medicine, for which pharmaco-imaging is indispensable to all players in the drug development cycle – from the pharmaceutical industry to clinicians – to ensure that the most appropriate treatments are being matched to the needs of the patient.

Explore our multi-modal pharmaco-imaging & targeted radiotherapy expertise for your preclinical projects:

  • Design & implementation of the radionuclide labeling of your chemical or biological molecules of interest
  • Biodistribution of therapeutic drugs using non-invasive techniques
  • Development of translational nuclear medicine biomarkers
  • Evaluation of targeted radiotherapy efficacy

[Congress] I/O Summit – 9-12 March – London

[Congress] I/O Summit – 9-12 March – London

Comprehensive solution to predict your drug efficacy in immuno-oncology

Immunological cell death (ICD) is a form of cancer cell death induced by radiotherapy, photodynamic therapy and chemotherapeutic agents.
Unlike apoptosis or necrosis, ICD can induce an effective immune response directed against the tumor whereby both dendritic cells and T lymphocytes are mediators of this response.
Dying cancer cells recruit and activate immune cells by releasing damage-associated molecular patterns (DAMPs).

Come & listen to Jean-François Mirjolet depicting our innovation solution for ICD.

[Talk] Immunogenic cell death, a novel screening platform integrating tumor cells and immune cells co-culture assays

[When] Tuesday 10th March -  9:40-10:10  -  Immunomodulatory Approaches stream


I fix a meeting!


[Congress] Innovation for Health – 13 February – Rotterdam – The Netherlands

[Congress] Innovation for Health – Rotterdam, The Netherlands – 13 February

Oncodesign has developed a service culture, based on innovation, quality & rapidity.  Come & listen to Xavier Morge as he will unveil how we make our expertise & research platforms available to our clients to move their strategic & complex discovery projects faster along with a high degree of quality.

A unique opportunity to meet leading innovators, to catch up on the latest trends, to present cutting-edge innovations and to engage in Life Sciences & Health. 

Date et time: 12 February 1.30 pm -2.45 pm

Title: Integrated Drug Discovery Services with a "Pharmaceutical Mindset”

Discover our unique Drug Discovery platform from patient to diagnostic and across various therapeutic areas!

I fix a meeting!